GLP-1 drugs such as Ozempic and Wegovy are providing new challenges for diet brands and gyms, who have seen a surge in demand ...

The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli ...

Originally approved to help with excess weight and obesity, the injectable Wegovy and its sibling-product Ozempic, which is ...

NBC 7 dives deep into the explosive popularity of the medications and explores both the life-changing benefits and the ...

Many types of physicians are now prescribing GLP-1 receptor agonist medications for weight loss, but that doesn’t mean they are all suitable providers for a safe weight loss experience. A provider who ...

More than 1.6 million Britons are set to get the ‘King Kong’ of fat jabs on the NHS over the next 12 years. Mounjaro – which ...

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filing in the gaps.

A surge of alternatives to newly popular weight-loss drugs is facing its biggest test yet after the FDA warned companies ...

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

While Ozempic is rising in popularity, experts say the drug is not designed or approved for weight loss. (Oct. 3, 2024) ...

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

Telehealth companies and patients are grappling with the potential loss of access to cheaper, alternative versions of Eli ...